Overview of the impact of CD4 levels on HCT outcomes in children and adults
| Reference . | Platform . | Adult/pediatric . | Outcome . | NRM by CD4+ . | No. of patients . | Type of study . |
|---|---|---|---|---|---|---|
| Admiraal et al6 | BM, PBSC, CB | Pediatric, young adult | Model-based dosing is associated with 90% CD4+ > 50 prior to day +100 and lower NRM in patients receiving ATG | >50: 5-y TRM 8% <50: 5-y TRM 34% | 214, multicenter | Retrospective, prospective |
| Lakkaraja et al39 | Ex vivo TCD | Pediatric, young adult | >50 CD4+ before day +100 improves TRM | >50: 5-y NRM 4% <50: 5-y NRM 31% | 180, single center | Retrospective |
| Barriga et al40 | BM, PBSC, CB | Pediatric | >50 CD4+ before day +100 improves TRM | >50: 2-y NRM 2.7% <50: 2-y NRM 22.2% | 101, single center | Prospective |
| Huang et al13 | PBSC (haplo-identical and HLA matched) | Adult | >50 CD4+ before day +100 associated with lower risk for EBV and CMV reactivation | NA | 122, single center | Retrospective |
| Troullioud Lucas et al21 | BM, PBSC, ex vivo TCD, CB | Pediatric, young adult | >50 CD4+ before day +100 improves outcomes >25 CD19+ before day +100 reduces NRM | NA | 503, multicenter | Retrospective |
| Admiraal et al5 | BM, CB | Pediatric | >50 CD4+ before day +100 improves TRM | >50: 2-y TRM 7% <50: 2-y TRM 43% | 58, single center | Prospective |
| Lakkaraja et al8 | Ex vivo TCD | Adult/pediatric | >50 CD4+ before day +100 improves NRM | >50: 5-y NRM 5% <50: 5-y NRM 36% | 554, single center | Retrospective |
| De Koning et al41 | BM, PBSC, in vitro TCD, CB | Pediatric | >50 CD4+ before day +100 improves OS and NRM after moderate to severe aGVHD | In patients with grade 3-4 aGVHD >50: 2-y NRM 30% <50: 2-y NRM 80% | 591, multicenter | Retrospective |
| Van Roessel et al42 | BM, PBSC, ex vivo TCD, CB | Pediatric, young adult | >50 CD4+ before day +100 is associated with improved survival | >50: 5-y NRM 3.2% <50: 5-y NRM 28.8% | 315, single center | Retrospective |
| Admiraal et al43 | BM, PBSC, CB | Pediatric | >50 CD4+ T cells associated with fewer viral reactivations | NA | 273, single center | Retrospective |
| Reference . | Platform . | Adult/pediatric . | Outcome . | NRM by CD4+ . | No. of patients . | Type of study . |
|---|---|---|---|---|---|---|
| Admiraal et al6 | BM, PBSC, CB | Pediatric, young adult | Model-based dosing is associated with 90% CD4+ > 50 prior to day +100 and lower NRM in patients receiving ATG | >50: 5-y TRM 8% <50: 5-y TRM 34% | 214, multicenter | Retrospective, prospective |
| Lakkaraja et al39 | Ex vivo TCD | Pediatric, young adult | >50 CD4+ before day +100 improves TRM | >50: 5-y NRM 4% <50: 5-y NRM 31% | 180, single center | Retrospective |
| Barriga et al40 | BM, PBSC, CB | Pediatric | >50 CD4+ before day +100 improves TRM | >50: 2-y NRM 2.7% <50: 2-y NRM 22.2% | 101, single center | Prospective |
| Huang et al13 | PBSC (haplo-identical and HLA matched) | Adult | >50 CD4+ before day +100 associated with lower risk for EBV and CMV reactivation | NA | 122, single center | Retrospective |
| Troullioud Lucas et al21 | BM, PBSC, ex vivo TCD, CB | Pediatric, young adult | >50 CD4+ before day +100 improves outcomes >25 CD19+ before day +100 reduces NRM | NA | 503, multicenter | Retrospective |
| Admiraal et al5 | BM, CB | Pediatric | >50 CD4+ before day +100 improves TRM | >50: 2-y TRM 7% <50: 2-y TRM 43% | 58, single center | Prospective |
| Lakkaraja et al8 | Ex vivo TCD | Adult/pediatric | >50 CD4+ before day +100 improves NRM | >50: 5-y NRM 5% <50: 5-y NRM 36% | 554, single center | Retrospective |
| De Koning et al41 | BM, PBSC, in vitro TCD, CB | Pediatric | >50 CD4+ before day +100 improves OS and NRM after moderate to severe aGVHD | In patients with grade 3-4 aGVHD >50: 2-y NRM 30% <50: 2-y NRM 80% | 591, multicenter | Retrospective |
| Van Roessel et al42 | BM, PBSC, ex vivo TCD, CB | Pediatric, young adult | >50 CD4+ before day +100 is associated with improved survival | >50: 5-y NRM 3.2% <50: 5-y NRM 28.8% | 315, single center | Retrospective |
| Admiraal et al43 | BM, PBSC, CB | Pediatric | >50 CD4+ T cells associated with fewer viral reactivations | NA | 273, single center | Retrospective |
CB, cord blood; CMV, cytomegalovirus; EBV, Epstein-Barr virus; NA, not available; PBSC, peripheral blood mononuclear cell; TRM, transplant-related mortality.